Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics

Corvus Pharmaceuticals, Inc. (CRVS): $3.24

0.04 (+1.25%)

POWR Rating

Component Grades








Add CRVS to Watchlist
Sign Up

Industry: Biotech




#138 of 380

in industry

CRVS Price/Volume Stats

Current price $3.24 52-week high $3.70
Prev. close $3.20 52-week low $0.61
Day low $3.10 Volume 387,791
Day high $3.49 Avg. volume 524,538
50-day MA $1.68 Dividend yield N/A
200-day MA $1.06 Market Cap 150.88M

CRVS Stock Price Chart Interactive Chart >

Corvus Pharmaceuticals, Inc. (CRVS) Company Bio

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.

CRVS Latest News Stream

Event/Time News Detail
Loading, please wait...

CRVS Latest Social Stream

Loading social stream, please wait...

View Full CRVS Social Stream

Latest CRVS News From Around the Web

Below are the latest news stories about CORVUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRVS as an investment opportunity.

Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2

Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics. | June 2, 2023

3 High-Potential Penny Stocks to Buy Now

When it comes to penny stocks to buy now, be aware of the risks.

Ian Cooper on InvestorPlace | May 31, 2023

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer of Corvus, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Healthcare Conference, which is being held in New York from June 7-9. The presentation will be on Wednesday, June 7, 2023 at 9:30 am ET. A webcast of the presentatio

Yahoo | May 31, 2023

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.

Yahoo | May 26, 2023

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland. “We continue to make strong progress in the development of ITK inhibition as a potential platform opportunity with a novel mechanism of a

Yahoo | May 17, 2023

Read More 'CRVS' Stories Here

CRVS Price Returns

1-mo 170.00%
3-mo 359.57%
6-mo 217.65%
1-year 205.66%
3-year -1.22%
5-year -75.04%
YTD 281.18%
2022 -64.73%
2021 -32.30%
2020 -34.56%
2019 48.23%
2018 -64.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!